NorthWest Biotherapeutics Inc (NWBO)

[abeta]

dstock07734

Nice find - thanks for posting

notice the reference to mesenchymal subtype

We characterized the molecular mechanisms and immune microenvironments of long-term survivors (LTS, n= 8), medium-term survivors (MTS, n= 13), and short-term survivors (STS, n = 17). Results: There was an enrichment of the mesenchymal subtype of glioblastoma in the long-term survival group. Additionally, decreased tumor cell density, upregulation of cell surface markers, and increased neuronal activity were associated with the longer survival cohorts. Two microglia populations, one associated with increased survival and one associated with decreased survival in the DC-treated cohorts, but not standard of care (SOC) cohorts, are also potentially implicated in response to DC immunotherapy. There were increases in functional activity of the immune environment in longer survivor cohorts

The irony here is that of the 4 TCGA GBM subtypes - mesenchymal is the
worst of the worst subtype - meaning chances of survival are -0- - yet
DCVax-L worked best within that subtype

Liau and Prins commented on this in a 2011 paper(s) of theirs
I don't have the links

========================
TCGA - actual cancer database started 2010
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818769/

subtypes - mesenchymal - classic - neural - proneural

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278117/
Microarray gene-expression profiling revealed that Jones and the others in his trial who are still alive had tumors with mesenchymal gene-expression signatures. In the Prins study, an analysis of tumor tissue with a mesenchymal gene-expression signature showed that these tumors have a higher number of CD3+ and CD8+ tumor-infiltrating lymphocytes compared with glioblastomas with other gene-expression signatures. The authors theorized that “the mesenchymal gene-expression profile may identify an immunogenic subgroup of glioblastoma that may be more responsive to immune-based therapies.”